SAGE Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2016, and provided an update on corporate strategy and financial guidance.

“The successful completion of our recent clinical studies has allowed us to begin a portfolio transformation at Sage. While it is commonly understood that GABA dysfunction is at the core of many CNS conditions, Sage is pursuing development of compounds that modulate GABA in a more complex and tailored manner, and we’re executing a new approach to drug development,” said Jeff Jonas, M.D., Chief Executive Officer of Sage.
MORE ON THIS TOPIC